China approves trials for the first nasal spray COVID-19 vaccine: report

China has approved three COVID-19 vaccine candidates for clinical trials. (Representative)

Beijing: Official media reported that China has approved the trial of its first nasal spray vaccine to combat the novel coronovirus, which claimed the lives of more than 904,000 people and infected more than 27 million people.

China’s only nasal spray vaccine against coronavirus is expected to begin Phase I clinical trials in November, and is recruiting 100 volunteers.

It is the only vaccine of its type approved by China’s National Medical Products Administration, the State-run Global Times reported.

The vaccine is a collaborative mission between Hong Kong and the Chinese mainland involving researchers from the University of Hong Kong, Xiaomi University and Beijing Savei Biological Pharmacy.

The vaccine stimulates the natural infection pathway of respiratory viruses to activate the immune response, said Yuen Kwok-yung, a microbiologist at the University of Hong Kong.

Nasal spray spray vaccination can generate dual protection for vaccine recipients – influenza and novel coronaviruses – if it also contains influenza viruses, including H1N1, H3N2 and B, the U.N. said three clinical trials It will take at least one more year to finish.

A Beijing-based immunologist told the daily that compared to injections, nasal spray is easier to vaccinate and will also be easier to mass-produce and distribute as it adopts mature influenza vaccine production technology.

The nasal spray vaccine uses a live attenuated influenza vaccine; China is using four other technology routes to introduce coronovirus vaccine inactivated vaccines, adenoviral vector-based vaccines, and DNA and mRNA vaccines. The report states that the inactivated vaccine vaccine is expected to hit the market.

Immunologists said that the new vaccine may not cause systemic side effects, but may cause side effects such as asthma and shortness of breath in the respiratory system.

Yuen Kwok-yung stated that ideally, scientists do not expect minor nasal blockage or side effects other than canker.

The report states that it is not yet clear whether the immunity produced by the nasal spray vaccine will persist for a long time.

China has approved three COVID-19 vaccine candidates for clinical trials. It has also authorized the emergency use of COVID-19 vaccines developed by select domestic companies.

Zheng Zhongwei, head of China’s coronavirus vaccine, said, “We have prepared a series of plan packages, including medical consent forms, side-effects monitoring plans, rescue plans, compensation plans. The development task force released official media here last month told.

An Emergency Use Authority, which is based on Chinese vaccine management law, allows unaffected vaccine candidates to be used among people who are at high risk of becoming infected in a limited period.

The Global Times has previously reported that employees of state-owned enterprises (SOEs) are preparing to go abroad, and frontline medics have been offered two alternatives to home-grown vaccine candidates developed by Cyanopharm for immediate use.

The novel Coronavirus, which originated from the city of Wuhan in China in December last year, has claimed the lives of 904,485 people and infected 27,902,002 globally. According to Johns Hopkins University data, the US is the country most affected by 190,887 deaths and 6,363,729 infections.

(Except for the headline, this story has not been edited by NDTV employees and published from a syndicated feed.)